Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;16(2):e008690.
doi: 10.1161/CIRCOUTCOMES.121.008690. Epub 2023 Feb 8.

Validity of Patient-Reported Outcomes Measurement Information System Physical, Mental, and Social Health Measures After Left Ventricular Assist Device Implantation and Implications for Patient Care

Elizabeth A Hahn  1 , Mary N Walsh  2 , Larry A Allen  3 , Christopher S Lee  4 , Quin E Denfeld  5 , Jeffrey J Teuteberg  6 , David G Beiser  7 , Colleen K McIlvennan  3 , JoAnn Lindenfeld  8 , Liviu Klein  9 , Eric D Adler  10 , Josef Stehlik  11 , Bernice Ruo  10 , Katy Bedjeti  1 , Peter D Cummings  1 , Alyssa M Vela  12 , Kathleen L Grady  12
Affiliations

Validity of Patient-Reported Outcomes Measurement Information System Physical, Mental, and Social Health Measures After Left Ventricular Assist Device Implantation and Implications for Patient Care

Elizabeth A Hahn et al. Circ Cardiovasc Qual Outcomes. 2023 Feb.

Abstract

Background: A better understanding is needed of the burdens and benefits of left ventricular assist device (LVAD) implantation on patients' physical, mental, and social well-being. The purpose of this report was to evaluate the validity of Patient-Reported Outcomes Measurement Information System (PROMIS) measures for LVAD patients and to estimate clinically important score differences likely to have implications for patient treatment or care.

Methods: Adults from 12 sites across all US geographic regions completed PROMIS measures ≥3 months post-LVAD implantation. Other patient-reported outcomes (eg, Kansas City Cardiomyopathy Questionnaire-12 item), clinician ratings, performance tests, and clinical adverse events were used as validity indicators. Criterion and construct validity and clinically important differences were estimated with Pearson correlations, ANOVA methods, and Cohen d effect sizes.

Results: Participants' (n=648) mean age was 58 years, and the majority were men (78%), non-Hispanic White people (68%), with dilated cardiomyopathy (55%), long-term implantation strategy (57%), and New York Heart Association classes I and II (54%). Most correlations between validity indicators and PROMIS measures were medium to large (≥0.3; p<0.01). Most validity analyses demonstrated medium-to-large effect sizes (≥0.5) and clinically important differences in mean PROMIS scores (up to 14.8 points). Ranges of minimally important differences for 4 PROMIS measures were as follows: fatigue (3-5 points), physical function (2-3), ability to participate in social roles and activities (3), and satisfaction with social roles and activities (3-5).

Conclusions: The findings provide convincing evidence for the relevance and validity of PROMIS physical, mental, and social health measures in patients from early-to-late post-LVAD implantation. Findings may inform shared decision-making when patients consider treatment options. Patients with an LVAD, their caregivers, and their clinicians should find it useful to interpret the meaning of their PROMIS scores in relation to the general population, that is, PROMIS may help to monitor a return to normalcy in everyday life.

Trial registration: ClinicalTrials.gov NCT03044535.

Keywords: adult; fatigue; female; heart failure; humans; patient reported outcome measures.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Rumsfeld J, Alexander K, Goff DJ, Graham M, Ho P, Masoudi F, Moser DK, Roger VL, Slaughter MS, Smolderen KG, et al. ; American Heart Association Council on Quality of Care and Outcomes Research, Council on Cardiovascular and Stroke Nursing, Council on Epidemiology and Prevention, Council on Peripheral Vascular Disease, and Stroke Council. Cardiovascular health: the importance of measuring patient-reported health status: a scientific statement from the American Heart Association. Circulation. 2013;127:2233–2249. doi: 10.1161/CIR.0b013e3182949a2e - PubMed
    1. Cowger JA, Naka Y, Aaronson KD, Horstmanshof D, Gulati S, Rinde-Hoffman D, Pinney S, Adatya S, Farrar DJ, Jorde UP. Quality of life and functional capacity outcomes in the momentum 3 trial at 6 months: a call for new metrics for left ventricular assist device patients. J Heart Lung Transplant. 2018;37:15–24. doi: 10.1016/j.healun.2017.10.019 - PubMed
    1. Goldstein DJ, Naka Y, Horstmanshof D, Ravichandran AK, Schroder J, Ransom J, Itoh A, Uriel N, Cleveland JC, Raval NY, et al. . Association of clinical outcomes with left ventricular assist device use by bridge to transplant or destination therapy intent: the multicenter study of maglev technology in patients undergoing mechanical circulatory support therapy with heartmate 3 (momentum 3) randomized clinical trial. JAMA Cardiol. 2020;5:411–419. doi: 10.1001/jamacardio.2019.5323 - PMC - PubMed
    1. Grady KLP, Naftel DP, Stevenson LMD, Amanda Dew MP, Weidner GP, Pagani FD, Kirklin JK, Myers S, Baldwin T, Young J. Overall quality of life improves to similar levels after mechanical circulatory support regardless of severity of heart failure before implantation. J Heart Lung Transplant. 2014;33:412–421. doi: 10.1016/j.healun.2013.10.017 - PMC - PubMed
    1. Grady KLP, Naftel DCP, Myers SBA, Dew MAP, Weidner GP, Spertus JA, Idrissi K, Lee HB, McGee EC, Kirklin JK. Change in health-related quality of life from before to after destination therapy mechanical circulatory support is similar for older and younger patients: analyses from Intermacs. J Heart Lung Transplant. 2015;34:213–221. doi: 10.1016/j.healun.2014.10.001 - PMC - PubMed

Publication types

Associated data